Login to Your Account

Other News To Note

Monday, May 2, 2011
Labopharm Inc., of Laval, Quebec, updated its strategic review process and, with the aim of preserving capital, entered discussions for restructuring its joint venture agreement with Gruppo Angelini SpA, of Rome, for commercializing depression drug Oleptro (trazodone hydrochloride extended-release tablets) in the U.S. Labopharm also is reviewing Oleptro for all territories outside the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription